PREPARE-IBD: Physician Responses to Disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease During COVID-19 Pandemic
- Conditions
- Coronavirus InfectionInflammatory Bowel Diseases
- Registration Number
- NCT04410484
- Lead Sponsor
- Hull University Teaching Hospitals NHS Trust
- Brief Summary
To find out what adaptations have been made by Inflammatory bowel disease physicians and patients in relation to therapies in flaring IBD patients during severe acute respiratory syndrome 2-COV and what the impact of these is on IBD patients with no symptomatic COVID-19 and in suspected/confirmed COVID-19. Also whether there any IBD related factors impacting the outcome of patients with COVID-19 symptoms or COVID-19 disease
- Detailed Description
An observational, retrospective, case-controlled study to determine the status of IBD during development of COVID-19 symptoms/positive COVID-19. The aim is to describe the adaptations in therapies for active IBD during SARS COV 2 in patients with active IBD and positive or negative COVID-19 symptoms. It will evaluate IBD outcomes following development of COVID-19 symptoms / positive COVID-19 and determine any predictors of outcomes in IBD patients with COVID-19 symptoms / positive COVID-19 as well as determine the impact on IBD outcomes resulting from adaptations to treatments during COVID-19
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3728
- Patients with IBD +/- flare +/- COVID 19 positivity
- Patients below 16
- Patient with inactive IBD
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Flare of IBD needing change in therapy or surgery 3 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Gastroenterology, Hull Royal Infirmary, Hull University Teaaching Hospitals NHS Trust
🇬🇧Hull, United Kingdom